TSX:DHT.UN - Post Discussion
Post by
retiredcf on Nov 28, 2022 8:31am
Small-Caps to Watch
Our roundup of Canadian small-caps of between $100-million and $3-billion in market capitalization making news
DRI Healthcare Trust announced it has acquired a royalty interest in worldwide sales of Xenpozyme (olipudase alfa) for US$30-million. The company said additional performance-based milestones of up to US$26.5-million could be paid if sales of the drug outperform expectations.
The company said Xenpozyme is the only product developed and approved for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease.
“Xenpozyme is a product that provides ASMD patients and their families with a disease-modifying therapy where none previously existed. The drug represents a transformational shift in therapies available to patients who suffer from ASMD,” said CEO Behzad Khosrowshahi.
Be the first to comment on this post